Pyo S
Arch Pharm Res. 1994; 17(2):93-9.
PMID: 10319138
DOI: 10.1007/BF02974230.
Ball M, Utsunomiya T, Ikemoto K, Kobayashi M, Pollard R, Suzuki F
Experientia. 1994; 50(8):774-9.
PMID: 7520870
DOI: 10.1007/BF01919381.
Gangemi J, HIGHTOWER J, Jackson R, Maher M, Welsh M, Sigel M
Infect Immun. 1983; 39(2):726-35.
PMID: 6832817
PMC: 348010.
DOI: 10.1128/iai.39.2.726-735.1983.
Schindler L, Brucher J, Kirchner H
Immunobiology. 1984; 166(1):62-71.
PMID: 6325328
PMC: 7134485.
DOI: 10.1016/S0171-2985(84)80144-8.
Wilson L, Smith J
Infect Immun. 1983; 41(3):1376-9.
PMID: 6309669
PMC: 264651.
DOI: 10.1128/iai.41.3.1376-1379.1983.
Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes.
Larsen H, Russell R, Rouse B
Infect Immun. 1983; 41(1):197-204.
PMID: 6305838
PMC: 264763.
DOI: 10.1128/iai.41.1.197-204.1983.
Inhibition of herpes simplex virus multiplication by activated macrophages: a role for arginase?.
Wildy P, Gell P, Rhodes J, Newton A
Infect Immun. 1982; 37(1):40-5.
PMID: 6286497
PMC: 347487.
DOI: 10.1128/iai.37.1.40-45.1982.
Approaches to assessing host resistance.
BRADLEY S, Morahan P
Environ Health Perspect. 1982; 43:61-9.
PMID: 6277617
PMC: 1568885.
DOI: 10.1289/ehp.824361.
Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
Hilfenhaus J, Christ H, Kohler R, Moser H, Kirchner H, Levy H
Med Microbiol Immunol. 1981; 169(4):225-35.
PMID: 6268955
DOI: 10.1007/BF02125522.
Use of viral infections in animal models to assess changes in the immune system.
Kern E
Environ Health Perspect. 1982; 43:71-9.
PMID: 6174323
PMC: 1568886.
DOI: 10.1289/ehp.824371.
Protection of mice against mouse hepatitis virus by Corynebacterium parvum.
Schindler L, STREISSLE G, Kirchner H
Infect Immun. 1981; 32(3):1128-31.
PMID: 6166566
PMC: 351569.
DOI: 10.1128/iai.32.3.1128-1131.1981.
The potential use of liposome-mediated antiviral therapy.
Koff W, Fidler I
Antiviral Res. 1985; 5(3):179-90.
PMID: 3896138
PMC: 7173127.
DOI: 10.1016/0166-3542(85)90050-6.
Abortive replication of vaccinia virus in activated rabbit macrophages.
Buchmeier N, Gee S, Murphy F, Rawls W
Infect Immun. 1979; 26(1):328-38.
PMID: 500210
PMC: 414616.
DOI: 10.1128/iai.26.1.328-338.1979.
Effect of pyran on latency after herpes simplex virus infections.
Morahan P, Cline P, Breinig M, Murray B
Antimicrob Agents Chemother. 1979; 15(4):547-53.
PMID: 464586
PMC: 352709.
DOI: 10.1128/AAC.15.4.547.
Comparison of various macrophage-inhibitory agents on vaginal and systemic herpes simplex virus type 2 infections.
McGeorge M, Morahan P
Infect Immun. 1978; 22(2):623-6.
PMID: 215548
PMC: 422201.
DOI: 10.1128/iai.22.2.623-626.1978.
Peritoneal macrophage activation indicated by enhanced chemiluminescence.
Schleupner C, Glasgow L
Infect Immun. 1978; 21(3):886-95.
PMID: 213391
PMC: 422080.
DOI: 10.1128/iai.21.3.886-895.1978.
Resistance to vaginal or systemic infection with herpes simplex virus type 2.
Breinig M, Wright L, McGeorge M, Morahan P
Arch Virol. 1978; 57(1):25-34.
PMID: 207239
DOI: 10.1007/BF01315634.
Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid.
Kern E, Richards J, Overall Jr J, Glasgow L
Antimicrob Agents Chemother. 1978; 13(1):53-60.
PMID: 204250
PMC: 352184.
DOI: 10.1128/AAC.13.1.53.
Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine.
Lodmell D, Ewalt L
Infect Immun. 1978; 19(1):225-30.
PMID: 203533
PMC: 414071.
DOI: 10.1128/iai.19.1.225-230.1978.
